<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180072</url>
  </required_header>
  <id_info>
    <org_study_id>T2219</org_study_id>
    <nct_id>NCT04180072</nct_id>
  </id_info>
  <brief_title>Atezolizumab Plus Bevacizumab With HCC and HBV Infection</brief_title>
  <official_title>Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Health Research Institutes, Taiwan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taipei Veterans General Hospital, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhua Christian Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taichung Veterans General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Health Research Institutes, Taiwan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm clinical trial. The main objective is to determine the efficacy of&#xD;
      atezolizumab+bevacizumab therapy in patients with advanced hepatocellular carcinoma and with&#xD;
      chronic hepatitis B virus infection. All eligible patients will receive atezolizumab +&#xD;
      bevacizumab therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Combination of atezolizumab, an immune checkpoint inhibitors (ICI), and bevacizumab, an&#xD;
      anti-angiogenic antibody, has shown promising anti-tumor activity and good safety profile in&#xD;
      patients with advanced hepatocellular carcinoma (HCC) and good liver function reserves&#xD;
      (Child-Pugh class A). Currently all trials of ICI-based therapy for HCC enrolled only&#xD;
      patients with very low HBV viral loads if they had chronic HBV infection because of the&#xD;
      concern of the risk of HBV reactivation on the severity and management of liver-related&#xD;
      adverse events, particularly immune-related hepatitis.&#xD;
&#xD;
      The investigators hypothesize that in patients with advanced HCC, chronic HBV infection, and&#xD;
      adequate liver function reserves, the safety profile of ICI-based therapy should be similar&#xD;
      to those in other patient populations as long as prophylactic anti-HBV treatment is given,&#xD;
      regardless the baseline HBV viral load. This is because in patients with patients with&#xD;
      lymphoma and chronic HBV infection, who have the highest risk of HBV reactivation after&#xD;
      cytotoxic or immunosuppressive therapy, no HBV-related complications of clinical significance&#xD;
      were noted as long as prophylactic anti-HBV treatment started before the administration of&#xD;
      cytotoxic or immunosuppressive therapy.&#xD;
&#xD;
      This is a single-arm clinical trial. Key eligibility criteria will include the following:&#xD;
      histologically proven, locally advanced or metastatic and/or unresectable HCC that is not&#xD;
      amenable to curative surgical and/or locoregional therapies; no prior systemic therapy for&#xD;
      HCC; documented chronic HBV infection with HBV DNA &gt; 2000 IU/mL obtained within 28 days prior&#xD;
      to initiation of study treatment; at least one measurable (per RECIST 1.1) lesion; ECOG&#xD;
      Performance Status of 0 or 1; and Child-Pugh class A.&#xD;
&#xD;
      All eligible patients will receive atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on&#xD;
      day 1 every 3 weeks. Study treatment will continue until documented tumor progression or&#xD;
      occurrence of unacceptable toxicity. All eligible subjects will receive anti-HBV treatment&#xD;
      (per local standard of care; e.g., entecavir) prior to start of study treatment and continue&#xD;
      anti-HBV treatment for the length of the study. The primary endpoint is overall response rate&#xD;
      defined as a complete or partial response, as determined by the investigator according to&#xD;
      RECIST v1.1. The secondary endpoints will include safety measures (e.g., the proportion of&#xD;
      subjects with ≥ grade 3 liver-related adverse events (AE) (according to NCI CTCAE v5.0),&#xD;
      incidence and severity of all adverse events/ immune-related adverse events, incidence of HBV&#xD;
      reactivation/ HBV-related hepatitis flare) and efficacy measures (e.g., objective response&#xD;
      rate, progression-free survival, duration of response, and overall survival). This study plan&#xD;
      to enroll 48 evaluable subjects, defined as subjects who receive 3 cycles of study treatment&#xD;
      and the first image evaluation for tumor response. The estimated time of enrollment will be 2&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>The last patient in has been treated for 6 months. All patients who have a PR or CR before that are responders</time_frame>
    <description>Complete or partial response, as determined by the investigator according to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with ≥ grade 3 liver-related adverse events (AE)</measure>
    <time_frame>12 weeks after the first drug administration.</time_frame>
    <description>Proportion of subjects with ≥ grade 3 liver-related adverse events (AE) according to NCI CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of total AE, liver related AE, and liver immune-related AE</measure>
    <time_frame>30 days after the last dose of study treatment or until initiation of new systemic anti-cancer therapy, whichever occurs first</time_frame>
    <description>Any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study drug and that does not necessarily have a causal relationship with this treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV reactivation</measure>
    <time_frame>Baseline up to approximately 2.5years.</time_frame>
    <description>(1) HBV DNA increase of ≧ 100 folds than baseline level, regardless of alanine aminotransferase (ALT) changes; (2) HBV DNA increase of ≧ 10 folds than baseline level, associated with significant ALT changes (defined as ≧ 3-fold increase in ALT, compared with baseline levels, and increase in ≧ 1 grade defined by CTCAE5.0); and (3) 2 consecutive increase in HBV DNA of ≧ 100 folds than previous nadir level, regardless of ALT changes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV-related hepatitis flare</measure>
    <time_frame>Every 4 weeks for 6 months in permanent discontinuation of study drug treatment</time_frame>
    <description>HBV reactivation plus ≧ 3-fold increase in alanine aminotransferase (ALT), compared with baseline levels, and increase in ≧ 1 grade defined by CTCAE v 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>The time from registration to the first occurrence of disease progression or death from any cause (whichever occurs first assessed up to 100 months)</time_frame>
    <description>The time from registration to the first occurrence of disease progression or death from any cause (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor progression</measure>
    <time_frame>The time from registration to the first occurrence of disease progression assessed up to 100 months</time_frame>
    <description>The time from registration to the first occurrence of disease progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>The time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first assessed up to 100 months)</time_frame>
    <description>The time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease stabilization rate</measure>
    <time_frame>Complete response + partial response + stable disease lasting for ≧16 weeks approximately1years.</time_frame>
    <description>Complete response + partial response + stable disease lasting for ≧16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AFP response</measure>
    <time_frame>9 weeks ± 1 week after the first drug administration</time_frame>
    <description>≥ 20% decrease from baseline at the first response assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>The time from registration to death from any cause assessed up to 100 months</time_frame>
    <description>The time from registration to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Atezolizumab plus bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atezolizumab 1200 mg IV plus bevacizumab 15 mg/kg IV on day 1 every 3 weeks. Study treatment will continue until documented tumor progression or occurrence of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 1200 mg IV on day 1 every 3 weeks</description>
    <arm_group_label>Atezolizumab plus bevacizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15 mg/kg IV on day 1 every 3 weeks</description>
    <arm_group_label>Atezolizumab plus bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 20 years, according to local regulation in Taiwan, at time of signing Informed&#xD;
             Consent Form.&#xD;
&#xD;
          -  Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by&#xD;
             histology.&#xD;
&#xD;
          -  Agreement to receive a mandatory tumor biopsy for enrollment into this study.&#xD;
&#xD;
          -  Disease that is not amenable to curative surgical and/or locoregional therapies, or&#xD;
             progressive disease after surgical and /or locoregional therapies.&#xD;
&#xD;
          -  No prior systemic therapy (including systemic investigational agents) for HCC.&#xD;
&#xD;
          -  Documented chronic HBV infection, defined by positive serum surface antigen (HBsAg),&#xD;
             and HBV DNA &gt; 2000 IU/mL obtained within 28 days prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
          -  Agreement to receive anti-HBV treatment (per local standard of care; e.g., entecavir)&#xD;
&#xD;
             1 to 2 weeks prior to study entry and willingness to continue treatment for the length&#xD;
             of the study.&#xD;
&#xD;
          -  At least one measurable (per RECIST 1.1) lesion. Patients who received prior local&#xD;
             therapy (e.g., radiofrequency ablation or transarterial chemoembolization, etc.) are&#xD;
             eligible provided the target lesion(s) have not been previously treated with local&#xD;
             therapy or the target lesion(s) within the field of local therapy have subsequently&#xD;
             progressed in accordance with RECIST version 1.1.&#xD;
&#xD;
          -  The liver tumors, if any, should occupy ≤ 50% of estimated liver volume.&#xD;
&#xD;
          -  ECOG Performance Status of 0 or 1 within 7 days prior to registration.&#xD;
&#xD;
          -  Child-Pugh class A (see Appendix) within 14 days prior to registration&#xD;
&#xD;
          -  Adequate hematologic and end-organ function, defined by the following laboratory test&#xD;
             results, obtained within 7 days prior to registration, unless otherwise specified:&#xD;
&#xD;
               -  ANC ≥ 1.5 x 109/L (1500/μL) without granulocyte colony-stimulating factor&#xD;
                  support; platelet count ≥ 75 x 109/L (75,000/μL) without transfusion; and&#xD;
                  hemoglobin ≥ 90 g/L (9 g/dL)(patients may be transfused to meet this criterion).&#xD;
&#xD;
               -  Liver transaminases (AST and ALT) ≤ 5 x upper limit of normal (ULN)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min (calculated&#xD;
                  using the Cockcroft-Gault formula)&#xD;
&#xD;
               -  Urine dipstick for proteinuria &lt; 2+ (within 7 days prior to initiation of study&#xD;
                  treatment).&#xD;
&#xD;
        Patients who have ≥ 2+ proteinuria on dipstick urinalysis at baseline will be eligible if&#xD;
        he/she have daily protein excretion of &lt; 1 g documented by a 24-hour urine collection.&#xD;
&#xD;
          -  Women of childbearing potential must agree to use contraceptive methods with a failure&#xD;
             rate of &lt; 1% per year (e.g., hormonal contraceptives that inhibit ovulation, copper&#xD;
             intrauterine devices) during the treatment period and for at least 5 months after the&#xD;
             last dose of atezolizumab, and 6 months after the last dose of bevacizumab.&#xD;
&#xD;
          -  Men must agree to use contraceptive measures (condom plus an additional contraceptive&#xD;
             method that together result in a failure rate of &lt; 1% per year) during the treatment&#xD;
             period and for 6 months after the last dose of bevacizumab.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of fibrolamellar HCC, sarcomatoid HCC, or mixed&#xD;
             cholangiocarcinoma and HCC.&#xD;
&#xD;
          -  Liver tumor(s) with main portal vein thrombi.&#xD;
&#xD;
          -  Imaging finding for HCC corresponding to any of the following:&#xD;
&#xD;
               -  HCC with ≧ 50% liver occupation&#xD;
&#xD;
               -  Clear invasion into the bile duct&#xD;
&#xD;
               -  Portal vein invasion at the main portal branch (Vp4)&#xD;
&#xD;
          -  Co-infection of HBV and HCV. Patients with a history of HCV infection but who are&#xD;
             negative for HCV RNA by PCR will be considered non-infected with HCV.&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
          -  History of esophageal/gastric varices or active peptic ulcers that are considered to&#xD;
             have high risk of bleeding.&#xD;
&#xD;
          -  History of upper gastrointestinal bleeding within 1 year.&#xD;
&#xD;
          -  Major systemic diseases that the investigator considers inappropriate for&#xD;
             participation.&#xD;
&#xD;
          -  History of severe allergic anaphylactic reactions to antibodies or fusion proteins&#xD;
&#xD;
          -  Prior allogeneic stem cell or solid organ transplantation.&#xD;
&#xD;
          -  Treatment with investigational therapy within 28 days prior to initiation of study&#xD;
             treatment.&#xD;
&#xD;
          -  Prior therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody (or any other&#xD;
             antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).&#xD;
&#xD;
          -  Local therapy to liver (e.g., radiofrequency ablation, transarterial&#xD;
             chemoembolization, etc.) within 28 days prior to initiation of study treatment or&#xD;
             non-recovery from side effects of any such procedure.&#xD;
&#xD;
          -  Radiotherapy within 28 days and abdominal/ pelvic radiotherapy within 60 days prior to&#xD;
             initiation of study treatment, except for palliative radiotherapy to bone lesions.&#xD;
&#xD;
        Symptomatic lesions (e.g., bone metastases or metastases causing nerve impingement)&#xD;
        amenable to palliative radiotherapy should be treated prior to enrollment. Patients should&#xD;
        be recovered from the effects of radiation. There is no required minimum recovery period.&#xD;
&#xD;
          -  Presence of central nervous system (CNS) or leptomeningeal metastases. Patients with a&#xD;
             history of CNS metastases are eligible for the study if he/she have received&#xD;
             radiotherapy or surgery for the CNS metastases, and complete response (no evidence of&#xD;
             residual CNS metastases) must be documented by brain CT scan at screening.&#xD;
&#xD;
          -  Any active autoimmune disease or history of known autoimmune disease except for&#xD;
             vitiligo, resolved childhood asthma/atopy, type I diabetes mellitus, residual&#xD;
             hypothyroidism due to autoimmune condition only requiring hormone replacement,&#xD;
             psoriasis not requiring systemic treatment, or conditions not expected to recur in the&#xD;
             absence of an external trigger are permitted to enroll.&#xD;
&#xD;
          -  History of drug-induced pneumonitis or idiopathic pneumonitis, or Evidence of active&#xD;
             pneumonitis on screening chest computed tomography (CT) scan. History of radiation&#xD;
             pneumonitis in the radiation field (fibrosis) is permitted.&#xD;
&#xD;
          -  Known active tuberculosis or other active infection.&#xD;
&#xD;
          -  Severe infection within 4 weeks prior to initiation of study treatment, including, but&#xD;
             not limited to, hospitalization for complications of infection, bacteremia, or severe&#xD;
             pneumonia&#xD;
&#xD;
          -  Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation&#xD;
             of study treatment. Core biopsy or other minor surgical procedure within 3 days prior&#xD;
             to the first dose of bevacizumab&#xD;
&#xD;
          -  History of malignancy other than HCC within 3 years prior to screening, with the&#xD;
             exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year&#xD;
             OS rate &gt; 90%), such as adequately treated carcinoma in situ of the cervix, non&#xD;
             melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or stage&#xD;
             I uterine cancer.&#xD;
&#xD;
          -  Requirement of systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             drug administration. Inhaled or topical steroids and adrenal replacement doses &gt; 10 mg&#xD;
             daily prednisone equivalents are permitted in the absence of active autoimmune&#xD;
             disease.&#xD;
&#xD;
          -  Inadequately controlled arterial hypertension (defined as systolic blood pressure (BP)&#xD;
             ≥150 mmHg and/or diastolic blood pressure &gt; 100 mmHg), based on an average of ≥ 3 BP&#xD;
             readings on ≥ 2 sessions, despite optimal antihypertensive therapy..&#xD;
&#xD;
          -  Current or recent (within 10 days of first dose of study treatment) use of aspirin (&gt;&#xD;
             325 mg/day), other anti-platelet therapy (e.g., dipyramidole, ticlopidine,&#xD;
             clopidogrel, and cilostazol), or full dose oral or parenteral anticoagulants or&#xD;
             thrombolytic agents for therapeutic (as opposed to prophylactic) purpose. However, the&#xD;
             use of direct oral anticoagulant therapies such as dabigatran (Pradaxa) and&#xD;
             rivaroxaban (Xarelto) is not recommended due to bleeding risk.&#xD;
&#xD;
          -  History of abdominal or tracheoesophageal fistula, gastrointestinal (GI) perforation,&#xD;
             or intra-abdominal abscess within 6 months prior to initiation of study treatment&#xD;
&#xD;
          -  Significant cardiovascular disease (such as New York Heart Association Class II or&#xD;
             greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3&#xD;
             months prior to initiation of study treatment), unstable arrhythmia, or unstable&#xD;
             angina&#xD;
&#xD;
          -  History of uncorrectable electrolyte disorder affecting serum levels of potassium,&#xD;
             calcium, or magnesium&#xD;
&#xD;
          -  Treatment of active infection with therapeutic oral or IV antibiotics within 2 weeks&#xD;
             prior to initiation of study treatment. Patients receiving prophylactic antibiotics&#xD;
             (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease&#xD;
             exacerbation) are eligible for the study.&#xD;
&#xD;
          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             treatment, or anticipation of need for such a vaccine during atezolizumab treatment or&#xD;
             within 5 months after the last dose of atezolizumab&#xD;
&#xD;
          -  Known hypersensitivity to Chinese hamster ovary cell products or to any component of&#xD;
             the atezolizumab or bevacizumab formulation&#xD;
&#xD;
          -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or&#xD;
             high risk for bleeding .Patients must undergo an esophagogastroduodenoscopy (EGD), and&#xD;
             all size of varices (small to large) must be assessed and treated per local standard&#xD;
             of care prior to enrollment. Patients who have undergone an EGD within 6 months of&#xD;
             prior to initiation of study treatment do not need to repeat the procedure.&#xD;
&#xD;
          -  A prior bleeding event due to esophageal and/or gastric varices within 6 months prior&#xD;
             to initiation of study treatment&#xD;
&#xD;
          -  Moderate or severe ascites&#xD;
&#xD;
          -  History of hepatic encephalopathy&#xD;
&#xD;
          -  Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or&#xD;
             recent peripheral arterial thrombosis) within 6 months prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
          -  History of hemoptysis (≥2.5 mL of bright red blood per episode) within 1 month prior&#xD;
             to initiation of study treatment&#xD;
&#xD;
          -  Evidence of bleeding diathesis or significant coagulopathy (in the absence of&#xD;
             therapeutic anticoagulation)&#xD;
&#xD;
          -  Evidence of abdominal free air that is not explained by paracentesis or recent&#xD;
             surgical procedure&#xD;
&#xD;
          -  Serious, non-healing or dehiscing wound, active ulcer, or untreated bone&#xD;
             fractureMetastatic disease that involves major airways or blood vessels, or centrally&#xD;
             located mediastinal tumor masses (&lt;30 mm from the carina) of large volume Patients&#xD;
             with vascular invasion of the portal or hepatic veins may be enrolled.&#xD;
&#xD;
          -  History of intra-abdominal inflammatory process within 6 months prior to initiation of&#xD;
             study treatment, including but not limited to active peptic ulcer disease,&#xD;
             diverticulitis, or colitis&#xD;
&#xD;
          -  Uncontrolled tumor-related pain Patients requiring pain medication must be on a stable&#xD;
             regimen at study entry. Symptomatic lesions (e.g., bone metastases or metastases&#xD;
             causing nerve impingement) amenable to palliative radiotherapy should be treated prior&#xD;
             to enrollment. Patients should be recovered from the effects of radiation. There is no&#xD;
             required minimum recovery period. Asymptomatic metastatic lesions that would likely&#xD;
             cause functional deficits or intractable pain with further growth (e.g., epidural&#xD;
             metastasis that is not currently associated with spinal cord compression) should be&#xD;
             considered for loco-regional therapy if appropriate prior to enrollment.&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently) Patients with indwelling&#xD;
             catheters (e.g., PleurX) are allowed.&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents (including, but not limited to,&#xD;
             interferon and interleukin 2 [IL-2]) within 4 weeks or 5 half-lives of the drug&#xD;
             (whichever is longer) prior to initiation of study treatment&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or&#xD;
             anticipation of need for systemic immunosuppressive medication during study treatment,&#xD;
             with the following exceptions: Patients who received acute, low-dose systemic&#xD;
             immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant&#xD;
             medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for&#xD;
             the study after Medical Monitor approval has been obtained. Patients who received&#xD;
             mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive&#xD;
             pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic&#xD;
             hypotension or adrenal insufficiency are eligible for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chiun Hsu, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ya-Ling Wu, BS</last_name>
    <phone>886-3-7206166</phone>
    <phone_ext>35119</phone_ext>
    <email>yalin@nhri.edu.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chiun Hsu, PhD</last_name>
    <phone>886-2-23123456</phone>
    <phone_ext>67789</phone_ext>
    <email>hsuchiun@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Li-Tzong Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I-Chen Wu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wen-Hung Hsu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsiang-Yao Shin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yao-Kuang Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Hsun Chen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-Chang Chuang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Yen Dai</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-Feng Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-I Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Po-Cheng Liang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui-Ching Wang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeng-Shiun Du</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsung-Jang Yeh</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yuh-Ching Gau</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Linkou</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shi-Ming Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Chen Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kun-Ming Chan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong-Shiue Chou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting-Jung Wu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Chung Hsieh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jen-Shi Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Hsun Hsieh, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiao-En Wu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Mo Hou Hou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chang-Fang Chiu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cheng-Yuan Peng, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsueh-Chou Lai, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Min Liao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wei-Fan Hsu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Wei Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsung-Yu Tsai, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Teng-Yu Lee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chung-Hsin Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hong-Zen Yeh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sheng-Shun Yang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shao-Wu Lee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I-Ta Lu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pi-Yi Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shao-Bin Cheng, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsiao-Tien Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chia-Chang Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Jie Huang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chia-Jui Yen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Chieh Yen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Tzong Chen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hui-jen Tsai, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nai-Jung Chiang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>I-Ting Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yen-Cheng Chiu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Chih Chiu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-Chieh Chien, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tung-Tsung Chang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hsin-Yu Kuo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tsang-En Wang, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ching-Wei Chang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hune-Seng Lin, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huan-Chau Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chiun Hsu, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ann-Lii Cheng, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chih-Hung Hsu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zhong-Zhe Lin, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ying-Chun Shen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yu-Yun Shao, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-Chun Lu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tsung-Hao Liu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hung-Chih Yang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tung-Hung Su, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tai-Chung Tseng, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sih-Han Liao, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rey-Heng Hu, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Chih Ho, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Hung Chen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bang-Bin Chen, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ja-Der Liang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shih-Jer Hsu, Master</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chun-Ming Hong, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>I-Cheng Lee, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi-Hsiang Huang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chien-Wei Su, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ming-Huang Chen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>San-Chi Chen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 24, 2019</study_first_submitted>
  <study_first_submitted_qc>November 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2019</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

